Key result
Inhibitors of the renin-angiotensin system, such as ACE inhibitors and ARBs, may reduce the incidence of new-onset diabetes by improving insulin sensitivity and protecting pancreatic beta-cells.
Why the study?
Do renin-angiotensin system inhibitors reduce the incidence of new-onset diabetes in patients at high risk of developing diabetes?
Population
Patients with or without hypertension and at high risk of developing diabetes
Design
Review
Authors
Loading...
Supports potential diabetes prevention with RAS inhibitors; leaves open confirmation in prospective randomized trials.
Do renin-angiotensin system inhibitors reduce the incidence of new-onset diabetes in patients at high risk of developing diabetes?
RAS inhibitors may prevent new-onset diabetes via hemodynamic effects and direct protection of pancreatic beta-cells, warranting prospective clinical trials.
Jandeleit‐Dahm et al. (2005) conducted a review in High risk of developing diabetes. Inhibitors of the renin-angiotensin system (ACE inhibitors and ARBs) was evaluated on Incidence of new-onset diabetes. Inhibitors of the renin-angiotensin system, such as ACE inhibitors and ARBs, may reduce the incidence of new-onset diabetes by improving insulin sensitivity and protecting pancreatic beta-cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: